Medindia LOGIN REGISTER
Medindia
Advertisement

Ebola-Treating Invetigational Monoclonal Antibody Safe for Adults

by Mohamed Fathima S on January 25, 2019 at 10:33 AM
Ebola-Treating Invetigational Monoclonal Antibody Safe for Adults

The investigational Ebola treatment mAb114 in eighteen healthy adults is effective, safe, well-tolerated and easy-to-administer, reveal findings published in The Lancet. Treatment with monoclonal antibody was given as part of phase I clinical trial.

The investigational treatment is currently being offered to Ebola patients in the Democratic Republic of the Congo (DRC) under compassionate use and as part of a Phase 2/3 clinical trial of multiple investigational treatments. mAb114, a single monoclonal antibody, binds to the core receptor binding domain of the Zaire ebolavirus surface protein, preventing the virus from infecting human cells. Scientists isolated the antibody from a human survivor of the 1995 Ebola outbreak in Kikwit, DRC. Prior studies showed that mAb114 can protect monkeys from lethal Ebola virus disease when given as late as five days after infection.

Advertisement


Participants in the Phase 1 clinical trial received a single intravenous infusion of mAb114, administered over approximately 30 minutes. Three participants received a 5 milligram(mg)/kilogram (kg) dose; five participants received a 25 mg/kg dose; and 10 participants received a 50 mg/kg dose. All infusions were well-tolerated. Four participants reported mild side effects, such as discomfort, muscle or joint pain, headache, nausea, and chills in the three days following the infusion.

As expected, levels of mAb114 in the blood increased as the dosage was increased. Investigators also observed relatively uniform levels of absorption, distribution, and elimination of mAb114 among participants.
Advertisement

The authors note several advantages for deploying mAb114 in an outbreak setting, including the ease and speed of its administration, and its formulation as a freeze-dried powder that does not require freezer storage. The powder is reconstituted with sterile water and added to saline for administration.

In addition to the ongoing Phase 2/3 clinical trial of mAb114 in the DRC, the VRC is planning to initiate another Phase 1 trial of the investigational treatment in Africa.



Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Latest Tropical Disease News

Monkeypox Outbreak Extends Across Five Indonesian Provinces
The viral infection of monkeypox has now spread to five provinces in Indonesia, said authorities.
Mpox Traced Back to 2016 Before 2022 Global Outbreak
Mpox, previously recognized as Monkeypox, has existed in human circulation since 2016, preceding the 2022 worldwide health emergency it initiated.
How Gut Bacteria Raise the Risk of Severe Malaria?
Gut bacteria composition is linked to a higher risk of severe malaria and may aid in developing new approaches to prevent severe malaria and its mortality.
Growing Monkeypox Outbreak in Indonesia Prompts Heightened Alert
Indonesia's Health Ministry is on high alert due to 14 confirmed monkeypox cases since its first detection on October 13.
Rare Zika Case Emerges in Cambodia After Seven Years
The Ministry of Health (MoH) in Cambodia has reported the first Zika virus case in the country since 2016.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Ebola-Treating Invetigational Monoclonal Antibody Safe for Adults Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests